{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:56:34Z","timestamp":1789588594852,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011848","name":"Novo Nordisk Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018956","name":"NIHR Cambridge Biomedical Research Centre","doi-asserted-by":"publisher","award":["IS-BRC-1215-20014"],"award-info":[{"award-number":["IS-BRC-1215-20014"]}],"id":[{"id":"10.13039\/501100018956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011284","name":"Valeant Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005241","name":"Institut de Recherche Clinique De Montr\u00c3\u00a9al","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011054","name":"Danish International Development Agency","doi-asserted-by":"publisher","award":["91202"],"award-info":[{"award-number":["91202"]}],"id":[{"id":"10.13039\/501100011054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000735","name":"University of Cambridge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001674","name":"Fondation Leducq","doi-asserted-by":"publisher","award":["13CVD03"],"award-info":[{"award-number":["13CVD03"]}],"id":[{"id":"10.13039\/501100001674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001734","name":"K\u00c3\u00b8benhavns Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015250","name":"NIHR Bristol Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015250","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.clinbiochem.2020.01.003","type":"journal-article","created":{"date-parts":[[2020,1,20]],"date-time":"2020-01-20T11:57:05Z","timestamp":1579521425000},"page":"20-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis"],"prefix":"10.1016","volume":"77","author":[{"given":"Martine","family":"Paquette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Chamberland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annik","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuella","family":"De Lucia Rolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon J.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Kaduka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil G.","family":"Seidah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk L.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Baass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clinbiochem.2020.01.003_b0005","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1053\/jhep.2003.50193","article-title":"Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference","volume":"37","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinbiochem.2020.01.003_b0010","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.clinbiochem.2020.01.003_b0015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.cld.2009.07.005","article-title":"Epidemiology and natural history of non-alcoholic steatohepatitis","volume":"13","author":"Argo","year":"2009","journal-title":"Clin. Liver Dis."},{"issue":"1","key":"10.1016\/j.clinbiochem.2020.01.003_b0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clinbiochem.2020.01.003_b0025","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.clinbiochem.2020.01.003_b0030","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/j.1572-0241.2003.07486.x","article-title":"The prevalence and etiology of elevated aminotransferase levels in the United States","volume":"98","author":"Clark","year":"2003","journal-title":"Am. J. Gastroenterol."},{"issue":"6037","key":"10.1016\/j.clinbiochem.2020.01.003_b0035","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.clinbiochem.2020.01.003_b0040","first-page":"315","article-title":"Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis","volume":"119","author":"Semple","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.clinbiochem.2020.01.003_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21101336","article-title":"The potential mechanisms of berberine in the treatment of nonalcoholic fatty liver disease","volume":"21","author":"Zhu","year":"2016","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.clinbiochem.2020.01.003_b0050","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.clinbiochem.2020.01.003_b0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/ATVBAHA.107.147538","article-title":"Fatty liver: a novel component of the metabolic syndrome","volume":"28","author":"Kotronen","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2020.01.003_b0060","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.clinbiochem.2020.01.003_b0065","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clinbiochem.2020.01.003_b0070","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.clinbiochem.2020.01.003_b0075","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"11","key":"10.1016\/j.clinbiochem.2020.01.003_b0080","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1373\/clinchem.2014.225946","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia","volume":"60","author":"Awan","year":"2014","journal-title":"Clin. Chem."},{"issue":"8","key":"10.1016\/j.clinbiochem.2020.01.003_b0085","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/met.2017.0027","article-title":"Association Between Plasma Proprotein Convertase Subtilisin\/Kexin Type 9 and the Presence of Metabolic Syndrome in a Predominantly Rural-Based Sub-Saharan African Population","volume":"15","author":"Paquette","year":"2017","journal-title":"Metab. Syndr. Relat. Disord."},{"issue":"7\u20138","key":"10.1016\/j.clinbiochem.2020.01.003_b0090","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinbiochem.2014.03.008","article-title":"Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins","volume":"47","author":"Kwakernaak","year":"2014","journal-title":"Clin. Biochem."},{"issue":"12","key":"10.1016\/j.clinbiochem.2020.01.003_b0095","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.clinbiochem.2014.03.022","article-title":"The effect of insulin on circulating PCSK9 in postmenopausal obese women","volume":"47","author":"Awan","year":"2014","journal-title":"Clin. Biochem."},{"issue":"15","key":"10.1016\/j.clinbiochem.2020.01.003_b0100","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.clinbiochem.2020.01.003_b0105","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.clinbiochem.2020.01.003_b0110","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2020.01.003_b0115","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.ATV.0000255311.26383.2f","article-title":"A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol","volume":"27","author":"Fasano","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2020.01.003_b0120","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"17","key":"10.1016\/j.clinbiochem.2020.01.003_b0125","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1177\/2047487317724342","article-title":"PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans","volume":"24","author":"Baragetti","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2020.01.003_b0130","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.clinbiochem.2020.01.003_b0135","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacl.2017.06.005","article-title":"A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease","volume":"11","author":"Di Filippo","year":"2017","journal-title":"J. Clin. Lipidol."},{"issue":"18","key":"10.1016\/j.clinbiochem.2020.01.003_b0140","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.clinbiochem.2020.01.003_b0145","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/07853890.2016.1188328","article-title":"Liver fat accumulation is associated with circulating PCSK9","volume":"48","author":"Ruscica","year":"2016","journal-title":"Ann. Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2020.01.003_b0150","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1743-7075-10-4","article-title":"Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets","volume":"10","author":"Cariou","year":"2013","journal-title":"Nutr. Metab. (Lond)."},{"key":"10.1016\/j.clinbiochem.2020.01.003_b0155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2018.09.008","article-title":"Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population","volume":"278","author":"Wargny","year":"2018","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.clinbiochem.2020.01.003_b0160","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/03014460801949870","article-title":"Obesity and regional fat distribution in Kenyan populations: impact of ethnicity and urbanization","volume":"35","author":"Christensen","year":"2008","journal-title":"Ann. Hum. Biol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2020.01.003_b0165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diabres.2009.03.007","article-title":"Prevalence of glucose intolerance and associated risk factors in rural and urban populations of different ethnic groups in Kenya","volume":"84","author":"Christensen","year":"2009","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"9","key":"10.1016\/j.clinbiochem.2020.01.003_b0170","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1373\/clinchem.2009.126987","article-title":"Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents","volume":"55","author":"Baass","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2020.01.003_b0175","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: Clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J. Lipid Res."},{"issue":"11","key":"10.1016\/j.clinbiochem.2020.01.003_b0180","article-title":"Validity of ultrasonography to assess hepatic steatosis compared to magnetic resonance spectroscopy as a criterion method in older adults","volume":"13","author":"De Lucia","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.clinbiochem.2020.01.003_b0185","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.clinbiochem.2020.01.003_b0190","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol."},{"issue":"16","key":"10.1016\/j.clinbiochem.2020.01.003_b0195","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.clinbiochem.2020.01.003_b0200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/01.ATV.0000251993.20372.40","article-title":"Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study","volume":"27","author":"Lee","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2020.01.003_b0205","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.atherosclerosis.2010.04.015","article-title":"Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients","volume":"211","author":"Cariou","year":"2010","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.clinbiochem.2020.01.003_b0210","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/cvr\/cvw053","article-title":"Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms","volume":"110","author":"Tavori","year":"2016","journal-title":"Cardiovasc. Res."},{"issue":"Suppl 2","key":"10.1016\/j.clinbiochem.2020.01.003_b0215","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1086\/381499","article-title":"HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms","volume":"38","author":"Pol","year":"2004","journal-title":"Clin. Infect. Dis."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912019309178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912019309178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:09:55Z","timestamp":1762114195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912019309178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":43,"alternative-id":["S0009912019309178"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.01.003","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2020.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}